drugset / Trial / NCT07355855
A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a prospective, multi-cohort, multi-center clinical trial targeting patients with intermediate-to-high-risk rhabdomyosarcoma who have not previously received systemic anti-tumor treatment. It aims to evaluate the efficacy and safety of all-trans retinoic acid combined with VAC chemotherapy.
Timeline
- Start
- 2026-01
- Primary completion
- 2029-01
- Completion
- 2029-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Cyclophosphamide | Other / unclassified | 1200 mg/m2 | Intravenous |
| Subject | Dactinomycin | Protein / enzyme biologic | 1.25 mg/m2 | Intravenous |
| Subject | Tretinoin | Small molecule | 20 mg | Oral |
| Subject | Tretinoin | Small molecule | 30 mg | Oral |
| Subject | Vincristine | Small molecule | 1.5 mg/m2 | Intravenous |